How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/triple-negative-breast-neoplasms.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Triple negative breast neoplasms — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Triple negative breast neoplasms (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Triple negative breast neoplasms, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Trodelvy	sacituzumab-govitecan	Immunomedics Inc		Tumor-associated calcium signal transducer 2		2020-01-01
Pembrolizuma	Pembrolizuma	Memorial Sloan Kettering Cancer Center		Programmed cell death protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Immunomedics Inc · 1 drug in Triple negative breast neoplasms
Memorial Sloan Kettering Cancer Center · 1 drug in Triple negative breast neoplasms

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Triple negative breast neoplasms:

Cite this brief

Drug Landscape (2026). Triple negative breast neoplasms — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/triple-negative-breast-neoplasms. Accessed 2026-06-10.

Triple negative breast neoplasms full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing